News headlines about Ligand Pharmaceuticals (NASDAQ:LGND) have trended positive recently, Alpha One Sentiment reports. Alpha One, a service of Accern, rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ligand Pharmaceuticals earned a news impact score of 0.31 on Alpha One’s scale. Alpha One also assigned press coverage about the biotechnology company an impact score of 95 out of 100, meaning that recent media coverage is extremely likely to have an effect on the stock’s share price in the near term.
These are some of the media headlines that may have effected Alpha One Sentiment’s analysis:
- Were Analysts Bearish Ligand Pharmaceuticals Inc. (NASDAQ … – Finance News Daily (finnewsdaily.com)
- Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 (finance.yahoo.com)
- Matthew W. Foehr Sells 5,621 Shares of Ligand Pharmaceuticals Inc. (LGND) Stock (americanbankingnews.com)
- Ligand Pharmaceuticals Inc. (LGND) Lowered to Strong Sell at Zacks Investment Research (americanbankingnews.com)
A number of research analysts recently weighed in on LGND shares. Zacks Investment Research raised Ligand Pharmaceuticals from a “hold” rating to a “buy” rating and set a $115.00 target price on the stock in a report on Monday, January 30th. Roth Capital started coverage on Ligand Pharmaceuticals in a report on Monday, February 27th. They set a “buy” rating and a $118.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $130.18.
Shares of Ligand Pharmaceuticals (NASDAQ:LGND) traded down 0.09% on Friday, reaching $113.81. The company’s stock had a trading volume of 155,134 shares. Ligand Pharmaceuticals has a 52-week low of $87.50 and a 52-week high of $139.79. The firm’s 50 day moving average is $109.15 and its 200-day moving average is $105.82. The stock’s market cap is $2.39 billion.
Ligand Pharmaceuticals (NASDAQ:LGND) last released its earnings results on Tuesday, May 9th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.55 by $0.16. Ligand Pharmaceuticals had a return on equity of 9.98% and a net margin of 8.51%. The firm had revenue of $29.27 million during the quarter, compared to analysts’ expectations of $30.25 million. During the same period in the prior year, the business earned $0.63 earnings per share. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. On average, equities research analysts forecast that Ligand Pharmaceuticals will post $2.70 EPS for the current year.
In other Ligand Pharmaceuticals news, insider Matthew W. Foehr sold 5,621 shares of the firm’s stock in a transaction on Friday, May 12th. The stock was sold at an average price of $112.20, for a total value of $630,676.20. Following the completion of the sale, the insider now directly owns 98,341 shares of the company’s stock, valued at $11,033,860.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jason Aryeh sold 37,247 shares of the firm’s stock in a transaction on Friday, May 12th. The stock was sold at an average price of $110.76, for a total value of $4,125,477.72. Following the completion of the sale, the director now directly owns 58,959 shares of the company’s stock, valued at $6,530,298.84. The disclosure for this sale can be found here. Insiders sold 85,747 shares of company stock valued at $9,306,974 over the last three months. Company insiders own 14.70% of the company’s stock.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Receive News & Ratings for Ligand Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.